DPAM
ALNY icon

Degroof Petercam Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Degroof Petercam Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$377K Hold
2,520
– – ﹤0.01% 531
2023
Q4 		$482K Buy
+2,520
New +$429K 0.01% 493

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Degroof Petercam Asset Management's ALNY Position: Q1 2024 in Review

Degroof Petercam Asset Management held its Alnylam Pharmaceuticals (ALNY) position steady in Q1 2024 at 2,520 shares worth $377K. The position accounts for ﹤0.01% of the portfolio, ranked #531.

Degroof Petercam Asset Management first reported a position in ALNY in Q4 2023 and has held it in 2 quarters since. The position peaked at $482K in Q4 2023. 499 funds tracked by Wall St. Rank hold ALNY as of Q1 2024.

  • Degroof Petercam Asset Management held 2,520 shares of Alnylam Pharmaceuticals worth $377K as of Q1 2024.
  • Degroof Petercam Asset Management left its Alnylam Pharmaceuticals share count unchanged in Q1 2024.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Degroof Petercam Asset Management's portfolio in Q1 2024, its #531 holding.
  • Degroof Petercam Asset Management first reported a position in Alnylam Pharmaceuticals in Q4 2023 and has held it in 2 quarters since.
  • Degroof Petercam Asset Management's Alnylam Pharmaceuticals position peaked at $482K in Q4 2023.
  • 499 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2024.

Based on Degroof Petercam Asset Management's 13F filing for Q1 2024, filed 13 May 2024.